

Edgar Filing: CYTOGEN CORP - Form 8-K

CYTOGEN CORP  
Form 8-K  
August 19, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

-----  
FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES ACT OF 1934

Date of report (Date of earliest event reported): August 14, 2002  
-----

CYTOGEN CORPORATION  
(Exact Name of Registrant as Specified in Charter)

Delaware

000-14879

222322400

-----  
(State or Other Jurisdiction  
of Incorporation)

(Commission File Number)

(IRS Employer  
Identification No.)

600 College Road East, CN 5308, Princeton, NJ

08540

-----  
(Address of Principal Executive Offices)

(Zip Code)

(609) 750-8200

-----  
(Registrant's telephone number,  
including area code)

-----  
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On August 14, 2002, Cytogen Corporation (the "Company") issued a press release reporting that it was notified by the Nasdaq Stock Market Inc. ("Nasdaq") regarding the Company's non-compliance with the minimum closing bid price requirement relating to Cytogen Common Stock. The Company has 90 calendar days or until November 12, 2002 to regain compliance with the minimum bid price requirement of \$1.00 per share.

There can be no assurance that the Company will be able to maintain the

Edgar Filing: CYTOGEN CORP - Form 8-K

listing of its Common Stock on Nasdaq National Market. Such delisting of its Common Stock could make it difficult for the Company to obtain future financing and materially adversely affect the trading in and price of the Common Stock.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

| Exhibit No.<br>----- | Description<br>-----                               |
|----------------------|--|
| 99.1                 | Press release of the Company dated August 14, 2002 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytogen Corporation

By: /s/ Lawrence R. Hoffman  
-----  
Lawrence R. Hoffman,  
Chief Financial Officer

Date: August 19, 2002